June 24, 2020 / 12:14 PM / 17 days ago

BRIEF-Alteogen Enters Into Global License Agreement With A Top Pharmaceutical Company For Use Of Its Hybrozyme Technology

June 24 (Reuters) - Alteogen Inc:

* ALTEOGEN ENTERS INTO A GLOBAL LICENSE AGREEMENT WITH A TOP TEN PHARMACEUTICAL COMPANY FOR USE OF ITS HYBROZYME™ TECHNOLOGY TO ENABLE SUBCUTANEOUS ADMINISTRATION OF BIOLOGIC PRODUCTS

* ALTEOGEN INC - WILL RECEIVE AN INITIAL PAYMENT OF USD 16 MILLION

* ALTEOGEN - ELIGIBLE TO GET ADDITIONAL MILESTONES UPON TTPC’S ACHIEVEMENT OF SPECIFIED DEVELOPMENT, REGULATORY & SALES MILESTONES, TOTALING $3.865 BILLION

* ALTEOGEN INC - GRANTED WORLDWIDE RIGHTS FOR TTPC TO DEVELOP MULTIPLE PRODUCTS IN COMBINATION WITH ALT-B4

* ALTEOGEN INC - WILL BE RESPONSIBLE FOR REGULATORY DEVELOPMENT AND COMMERCIAL SUPPLY OF ALT-B4 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below